NASDAQ:CAPS Capstone Therapeutics Q1 2026 Earnings Results & Report $1.74 -0.01 (-0.29%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Capstone Therapeutics missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 20, 2026. The company reported EPS of -$6.30 versus the -$5.70 consensus estimate, while revenue of $12.64 million topped the $10.80 million estimate by $1.84 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 20, 2026TimeBefore Market OpensConference Call7:00 AM ET Capstone Therapeutics EPS ResultsActual EPS-$6.30Consensus EPS -$5.70Beat/MissMissed by -$0.60One Year Ago EPSN/ACapstone Therapeutics Revenue ResultsActual Revenue$12.64 millionExpected Revenue$10.80 millionBeat/MissBeat by +$1.84 millionYoY Revenue GrowthN/AConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Capstone Therapeutics Q1 2026 Earnings FAQ Did Capstone Therapeutics beat earnings estimates for Q1 2026? Capstone Therapeutics (NASDAQ:CAPS) reported earnings of -$6.30 per share for Q1 2026, missing the consensus estimate of -$5.70. The report was announced on Wednesday, May 20, 2026. What was Capstone Therapeutics' revenue for Q1 2026? Capstone Therapeutics reported revenue of $12.64 million for Q1 2026, against a consensus estimate of $10.80 million. Capstone Therapeutics Earnings HeadlinesCapstone Reports Q3 2026 Results: Revenue Up 46% to $20.0 Million, Gross Profit Up 76%, Operating Income of $0.4 MillionNovember 12, 2026 | businesswire.comCapstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million RemainingAugust 26, 2026 | businesswire.comWhy my scanner is $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 16 at 1:00 AM | Profits Run (Ad)Capstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as GuidedAugust 12, 2026 | businesswire.comCapstone Receives Additional 180-Day Nasdaq Compliance PeriodJuly 9, 2026 | businesswire.comCapstone Extends Credit Facilities with Beacon Bank and Stream Finance on Identical TermsJune 22, 2026 | businesswire.comSee More Capstone Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email. Email Address About Capstone TherapeuticsCapstone Therapeutics (NASDAQ:CAPS) was a biotechnology company focused on developing peptide-based therapies. Its lead investigational candidate was A6, a synthetic peptide studied for potential use in treating ovarian cancer.The company was formerly known as OrthoLogic Corporation and adopted the Capstone Therapeutics name in 2008. Its work centered on advancing A6 rather than marketing an established portfolio of medicines.View Capstone Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need?Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.